- Patients with stage I-II small cell lung cancer (SCLC) have significantly better OS and progression-free survival (PFS) after chemoradiotherapy (CRT) than patients with stage III disease.
Why this matters
- The findings could help clinicians and SCLC patients choose the best course of therapy.
- Post-hoc secondary analysis of the multicenter, randomized phase 3 CONVERT trial.
- 509 patients (4 stage I, 82 stage II, and 423 stage III) received twice-daily (45 Gy in 30 fractions) or once-daily (66 Gy in 33 fractions) CRT and prophylactic cranial irradiation, if indicated.
- Funding: Cancer Research UK Clinical Trials Awards and Advisory Committee and others.
- Among stage I-II patients, 40.7% received twice-daily radiotherapy (RT) and 59.3% received once-daily treatment; OS was similar between arms (P=.38).
- Median OS was 50 months in stage I-II disease and 25 months in stage III disease (HRmortality, 0.60; P=.001).
- Compared with stage III disease, patients with stage II SCLC experienced:
- Better 2-year OS (64% vs 51%) and 5-year OS (49% vs 28%).
- Better median local (38 vs 17 months; P=.003) and metastatic PFS (40 vs 16 months; P<.001>
- Small number of stage I-II patients.